Inventories

9 Months Ended

Sep. 30, 2017

Inventory Disclosure [Abstract]

Inventories

Note 3:  Inventories

The inventories of the Company consisted primarily of inventories of USC and approximately $194,000 of raw materials for our FDA approved Epinephrine PFS product. As of September 30, 2017, inventories consisted of the following: 

Finished Goods	$	178,442
Raw Material		607,759
Devices		209,887
	$	996,088

Reserve for obsolescence as of September 30, 2017, was $31,627.